Vigonvita Life Sciences' 2025 Loss Widens

MT Newswires Live

04/01

Vigonvita Life Sciences (HKG:2630) booked 355.7 million yuan in loss for 2025, 68% higher from the 211.4 million yuan loss booked in 2024, according to a Hong Kong bourse filing Tuesday.

Shares of the drug discovery firm gained over 3% in late morning trade Wednesday.

Loss per share was 2.33 yuan, compared with 1.45 yuan in the prior year.

Revenue rose to 102.1 million yuan from 11.8 million yuan in 2024.

The firm attributed the increase in revenue to the marketing approval of its TPN171 drug during the year, as well as milestone payments tied to the VV116 medicine.

The company did not declare any dividend for the year.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2624569473"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2624569473\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2624569473?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 12:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624569473","market":"nz","top_or_hot":-1,"title":"Vigonvita Life Sciences' 2025 Loss Widens","media":"MT Newswires Live","content":"<html><body><p> Vigonvita Life Sciences (HKG:2630) booked 355.7 million yuan in loss for 2025, 68% higher from the 211.4 million yuan loss booked in 2024, according to a Hong Kong bourse filing Tuesday.</p><p>Shares of the drug discovery firm gained over 3% in late morning trade Wednesday.</p><p>Loss per share was 2.33 yuan, compared with 1.45 yuan in the prior year.</p><p>Revenue rose to 102.1 million yuan from 11.8 million yuan in 2024.</p><p>The firm attributed the increase in revenue to the marketing approval of its TPN171 drug during the year, as well as milestone payments tied to the VV116 medicine.</p><p>The company did not declare any dividend for the year.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vigonvita Life Sciences' 2025 Loss Widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVigonvita Life Sciences' 2025 Loss Widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-01 12:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Vigonvita Life Sciences (HKG:2630) booked 355.7 million yuan in loss for 2025, 68% higher from the 211.4 million yuan loss booked in 2024, according to a Hong Kong bourse filing Tuesday.</p><p>Shares of the drug discovery firm gained over 3% in late morning trade Wednesday.</p><p>Loss per share was 2.33 yuan, compared with 1.45 yuan in the prior year.</p><p>Revenue rose to 102.1 million yuan from 11.8 million yuan in 2024.</p><p>The firm attributed the increase in revenue to the marketing approval of its TPN171 drug during the year, as well as milestone payments tied to the VV116 medicine.</p><p>The company did not declare any dividend for the year.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2624569473","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624569473","pubTimestamp":1775018812,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Vigonvita Life Sciences  booked 355.7 million yuan in loss for 2025, 68% higher from the 211.4 million yuan loss booked in 2024, according to a Hong Kong bourse filing Tuesday.Shares of the drug discovery firm gained over 3% in late morning trade Wednesday.Loss per share was 2.33 yuan, compared with 1.45 yuan in the prior year.Revenue rose to 102.1 million yuan from 11.8 million yuan in 2024.The firm attributed the increase in revenue to the marketing approval of its TPN171 drug during the year, as well as milestone payments tied to the VV116 medicine.The company did not declare any dividend for the year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","02630":"旺山旺水-B"},"translate_title":"VigonVita Life Sciences 2025年亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02630":1},"content_text":"Vigonvita Life Sciences (HKG:2630) booked 355.7 million yuan in loss for 2025, 68% higher from the 211.4 million yuan loss booked in 2024, according to a Hong Kong bourse filing Tuesday.Shares of the drug discovery firm gained over 3% in late morning trade Wednesday.Loss per share was 2.33 yuan, compared with 1.45 yuan in the prior year.Revenue rose to 102.1 million yuan from 11.8 million yuan in 2024.The firm attributed the increase in revenue to the marketing approval of its TPN171 drug during the year, as well as milestone payments tied to the VV116 medicine.The company did not declare any dividend for the year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}